Back to School: How biopharma can reboot drug development. Access exclusive analysis here

P1A: Phase IIb data

In a double-blind Phase IIb trial in 112 patients receiving ampicillin for

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE